youtube_live
Q3 2026 earnings • released • Revenue beat +2.96%
See resultschevron_right
GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$8.56
arrow_upward
+0.59%(+0.050) 1D
$8.63
arrow_upward
+0.86% (+0.074)bedtimeAfter hours
Closed: Nov 3, 4:00:02 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRFS...
Open
$8.56
High
$8.72
Low
$8.40
Mkt. cap
7.44B
Avg. vol.
743.90K
Volume
0.00
Dividend
1.10%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
11.51
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
Open
$8.56
High
$8.72
Low
$8.40
Mkt. cap
7.44B
Avg. vol.
743.90K
Volume
0.00
Dividend
1.10%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
11.51
52-wk high
$9.90
52-wk low
$6.96
EPS
$0.74
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
News stories
From web sources and news partners
Yahoo Finance
·
11 hours ago
Grifols (BME:GRF) Stock Price Trails Q3 Results As Debt Questions Linger
Seeking Alpha
·
12 hours ago
Grifols: Plasma, Profits, And Recovery Gathering Momentum (NASDAQ:GRFS)
Yahoo Finance
·
19 hours ago
Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth
The Globe and Mail
·
1 day ago
Grifols (GRFS) Q3 2026 Earnings Call Transcript
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B
CEONacho Abia
Employees25K
FoundedNov 18, 1940
Headquarters-
SectorBiotechnology
Industry-
Websitegrifols.com
Analyst ratings
Based on 1 analyst giving stock ratings to GRFS in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for GRFS in the last 3 months
Highest
Current $8.56
$9.00 (+5.14%)
Average
$9.00 (+5.14%)
Lowest
$9.00 (+5.14%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Sophia Graeff Buhl-Nielsen J.P. Morgan | Hold | Reiterated | $9.00 | +5.1% | 10/26/2026 |
Last report
Nov 2, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €0.30
Revenue / Est. (EUR)
2.04B / 1.98B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.87B | 1.98B | 1.70B | 1.87B |
Cost of goods sold | 1.11B | 1.28B | 1.06B | 1.19B |
Cost of revenue | 1.11B | 1.28B | 1.06B | 1.19B |
Research and development expenses | 97.01M | 90.82M | 90.00M | 86.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 273.76M | 262.86M | 269.00M | 301.00M |
Operating expense | 370.34M | 353.11M | 359.00M | 387.00M |
Total operating expenses | 1.48B | 1.63B | 1.42B | 1.58B |
Operating income | 381.18M | 347.38M | 280.00M | 298.00M |
Other non operating income | - | -33.00M | - | -13.00M |
EBT including unusual items | 198.13M | 111.10M | 112.00M | 247.00M |
EBT excluding unusual items | 227.20M | 183.10M | 143.00M | 216.00M |
Income tax expense | 54.71M | -14.68M | 24.00M | 64.00M |
Effective tax rate | 27.61% | -13.21% | 21.43% | 25.91% |
Other operating expenses | -430.00K | -570.00K | - | - |
Net income | 126.96M | 98.25M | 73.00M | 154.00M |
Net profit margin | 6.81% | 4.96% | 4.29% | 8.22% |
Earnings per share | - | - | - | - |
Interest and investment income | - | 36.00M | - | 120.00M |
Interest expense | -156.07M | -107.99M | -139.00M | -179.00M |
Net interest expenses | -156.07M | -71.99M | -139.00M | -59.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 484.03M | 422.88M | 384.00M | 364.00M |
Gain or loss from assets sale | - | 2.00M | - | -6.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events